WallStreetZenWallStreetZen

NASDAQ: AKTX
Akari Therapeutics PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AKTX

Based on 2 analysts offering 12 month price targets for Akari Therapeutics PLC

Min Forecast
$1.60+106.45%
Avg Forecast
$3.30+325.81%
Max Forecast
$5.00+545.16%

Should I buy or sell AKTX stock?

Based on 2 analysts offering ratings for Akari Therapeutics PLC.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AKTX stock forecasts and price targets.

AKTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-09-09
lockedlocked$00.00+00.00%2025-07-18

1 of 1

AKTX revenue forecast

What is AKTX's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$110.9M

AKTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AKTX$0.78$3.30+325.81%Strong Buy
ATNM$1.62$4.00+146.91%Buy
DTIL$4.50$60.00+1,233.33%Buy
GUTS$0.98$6.20+531.36%Strong Buy
VERU$3.54$20.00+464.97%Buy
View Top Biotech Stocks

Akari Therapeutics Stock Forecast FAQ

Is Akari Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: AKTX) stock is to Strong Buy AKTX stock.

Out of 2 analysts, 1 (50%) are recommending AKTX as a Strong Buy, 1 (50%) are recommending AKTX as a Buy, 0 (0%) are recommending AKTX as a Hold, 0 (0%) are recommending AKTX as a Sell, and 0 (0%) are recommending AKTX as a Strong Sell.

If you're new to stock investing, here's how to buy Akari Therapeutics stock.

What is AKTX's revenue growth forecast for 2031-2031?

(NASDAQ: AKTX) Akari Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of N/A, and while it is not forecast to beat the US market's average forecast revenue growth rate of N/A.

Akari Therapeutics's revenue in 2025 is $0.

In 2031, AKTX is forecast to generate $7,235,904,166,746 in revenue, with the lowest revenue forecast at $7,235,904,166,746 and the highest revenue forecast at $7,235,904,166,746.

What is AKTX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AKTX price target, the average AKTX price target is $3.30, with the highest AKTX stock price forecast at $5.00 and the lowest AKTX stock price forecast at $1.60.

On average, Wall Street analysts predict that Akari Therapeutics's share price could reach $3.30 by Sep 9, 2026. The average Akari Therapeutics stock price prediction forecasts a potential upside of 325.81% from the current AKTX share price of $0.78.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.